Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

156
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
156
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

161
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
161
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

13.4K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
13.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Protein Consumption and Cognitive Health in Aging: Associations with Sarcopenia and Dietary Options, a Narrative Review.

Nutrients·2026
Same author

A Low-Cost, Open-Source, In Situ, Near-Real-Time Sensor for the Detection of Nitrate and Ammonia in Environmental Waters.

ACS ES&T water·2026
Same author

Real-time control of wetlands alters waterbird activity and water quality outcomes.

Journal of environmental management·2026
Same author

Accelerating innovation in sustainable development through transdisciplinary impact research.

iScience·2026
Same author

Measuring Pediatric Disaster Readiness of United States Emergency Departments.

Journal of the American College of Emergency Physicians open·2026
Same author

The next frontier in stormwater management and models: Multispectral and hyperspectral imaging of build-up and wash-off.

Journal of environmental management·2025

Related Experiment Video

Updated: Apr 27, 2026

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes
10:33

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

10.4K

Multifunctional, self-assembling anionic peptide-lipid nanocomplexes for targeted siRNA delivery.

Aristides D Tagalakis1, Do Hyang D Lee1, Alison S Bienemann2

  • 1Molecular Immunology Unit, UCL Institute of Child Health, 30 Guilford Street, London, WC1N 1EH, UK.

Biomaterials
|July 3, 2014
PubMed
Summary

Anionic nanoparticles overcome limitations of cationic formulations for in vivo gene silencing. These novel nanoparticles show resistance to serum aggregation and effectively reduce BACE1 in neuronal disease models.

Keywords:
Anionic liposomeGene silencingGene therapyNanoparticleTargetedsiRNA

More Related Videos

Porous Silicon Microparticles for Delivery of siRNA Therapeutics
08:31

Porous Silicon Microparticles for Delivery of siRNA Therapeutics

Published on: January 15, 2015

10.7K
Assembly and Characterization of Polyelectrolyte Complex Micelles
08:44

Assembly and Characterization of Polyelectrolyte Complex Micelles

Published on: March 2, 2020

10.7K

Related Experiment Videos

Last Updated: Apr 27, 2026

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes
10:33

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

10.4K
Porous Silicon Microparticles for Delivery of siRNA Therapeutics
08:31

Porous Silicon Microparticles for Delivery of siRNA Therapeutics

Published on: January 15, 2015

10.7K
Assembly and Characterization of Polyelectrolyte Complex Micelles
08:44

Assembly and Characterization of Polyelectrolyte Complex Micelles

Published on: March 2, 2020

10.7K

Area of Science:

  • Biotechnology
  • Nanomedicine
  • Molecular Biology

Background:

  • Cationic nanoparticles efficiently deliver siRNA in vitro but face challenges in vivo, including rapid clearance, serum protein association, and toxicity.
  • Anionic formulations offer potential solutions but struggle with self-assembly and transfection efficiency.

Purpose of the Study:

  • To develop and evaluate novel anionic, siRNA nanocomplexes for improved in vivo gene delivery and therapeutic applications.
  • To overcome the limitations of cationic nanoparticles by utilizing anionic PEGylated liposomes and cationic targeting peptides.

Main Methods:

  • Anionic siRNA nanocomplexes were formulated using anionic PEGylated liposomes and cationic targeting peptides.
  • Biophysical characterization included assessment of particle size, aggregation in serum, and gene silencing efficiency.
  • In vivo studies involved administration to rat brains via convection-enhanced delivery to target BACE1 in a neuronal disease model.

Main Results:

  • Anionic PEGylated nanocomplexes formed stable, spherical particles resistant to serum aggregation.
  • Significant gene silencing of BACE1 was achieved in vivo following a single injection.
  • Specificity of RNA interference was confirmed through 5' RACE-PCR and Western blot analysis.

Conclusions:

  • Developed anionic nanoparticles offer a promising alternative to cationic formulations for in vivo siRNA delivery.
  • These nanoparticles demonstrate improved stability and efficacy for potential therapeutic applications in neuronal diseases.
  • Targeted delivery and effective gene silencing highlight the potential of this nanomedicine approach.